The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.375 (24.59%)
Spread: 0.20 (11.111%)
Open: 1.525
High: 1.90
Low: 1.90
Prev. Close: 1.525
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Shield Therapeutics Plc

6 Jun 2023 12:00

RNS Number : 8166B
Peel Hunt LLP
06 June 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shield Therapeutics Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Shield Therapeutics Plc

(d) Date dealing undertaken:

05 June 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Purchase

102,102

6.66 GBx

6.63 GBx

Ordinary Shares

Sale

101,573

6.80 GBx

6.73 GBx

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

Date of disclosure:

06 June 2023

 

Contact name:

Alexandra Forner

Telephone number:

0207 847 4740

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGCGDLDSGDGXL
Date   Source Headline
26th Jul 20197:00 amRNSFDA approves Feraccru® with a broad label
2nd Jul 201912:00 pmRNSAdditional Listing
13th Jun 20192:16 pmRNSResult of AGM
3rd Jun 20197:00 amRNSUpdate on Legal Proceedings
13th May 201912:00 pmEQSHardman & Co Research: Shield Therapeutics (STX): All in the execution
8th May 20197:00 amRNSAppointment of Joint Broker
2nd May 20197:00 amRNSInvestor presentation
1st May 201911:58 amRNSAdditional Listing
30th Apr 20197:00 amRNS2018 Annual Report and 2019 AGM Notice
26th Apr 20196:05 pmRNSPDMR Acquisition of Shares
24th Apr 20197:00 amRNSMajor extension to approval in Switzerland
17th Apr 20195:06 pmRNSGrant of share options
17th Apr 20195:01 pmRNSPDMR Acquisition of Shares and Additional Listing
17th Apr 20194:56 pmRNSPDMR Acquisition of Shares
11th Apr 20194:40 pmRNSHolding(s) in Company
8th Apr 20193:42 pmRNSAdditional Listing
3rd Apr 20197:00 amRNSFinal Results
1st Apr 20195:44 pmRNSAdditional Listing
1st Apr 201912:00 pmRNSChange of Adviser
27th Mar 20197:00 amRNSNotice of Results
14th Mar 20193:31 pmRNSPositive decision on Feraccru®'s process patent
4th Mar 20197:00 amRNSPositive results for Feraccru® in AEGIS-H2H study
29th Jan 20197:00 amRNSPositive results of AEGIS-CKD study
28th Jan 20197:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
24th Jan 20197:00 amRNSBusiness and trading update
23rd Jan 201910:19 amRNSInvestor presentations
22nd Jan 20197:00 amRNSAppointment of Chairman
13th Dec 20187:00 amRNSUS New Drug Application PDUFA date for Feraccru
5th Dec 201810:04 amRNSUK launch of Feraccru® by Norgine
3rd Dec 20187:00 amRNSNew Drug Application for Feraccru®
9th Nov 20183:46 pmRNSHolding(s) in Company
8th Nov 20186:21 pmRNSHolding(s) in Company
1st Oct 20181:54 pmRNSNotification Of Major Holdings
1st Oct 20187:00 amRNSSubmission of an NDA for Feraccru® with the FDA
24th Sep 20181:06 pmRNSDirector/PDMR Shareholding
24th Sep 20181:02 pmRNSHolding(s) in Company
19th Sep 20187:14 amRNSLicence for the commercialisation of Feraccru
19th Sep 20187:12 amRNSInterim Results
13th Sep 20187:00 amRNSAEGIS-H2H Completion of Recruitment
26th Jul 20187:00 amRNSAppointment of Non-Executive Director
23rd Jul 20187:00 amRNSBusiness Update
9th Jul 20184:27 pmRNSHoldings in Company
9th Jul 20184:26 pmRNSHoldings in Company
28th Jun 201811:56 amRNSResult of AGM
28th Jun 20187:00 amRNSData from real-world clinical use of Feraccru
14th Jun 20187:00 amRNSPositive top-line results from AEGIS-PAED PK study
5th Jun 20187:00 amRNSDirectorate Change
5th Jun 20187:00 amRNS2017 Annual Report and 2018 AGM Notice
15th May 20186:21 pmRNSGrant of share options
4th May 20189:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.